PR
ProPhase Labs, Inc.
PRPH · OTC
$0.02 +10.71% (+$0.00)
1M -53.33%
Market Cap $196.2K
P/E Ratio -
Div. Yield -
ROE 1,358.66%
Bulios Fair Price
$0.02
29.0% upside
Current Price
$0.016
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PRPH is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/S 0.06x
PEG N/A
P/B N/A
Growth
0 /100
Declining Rev. growth 67.16%
FCF growth N/A
Book val. growth N/A
Profitability
4 /100
Weak Net margin 717.43%
Op. margin 498.73%
FCF margin 972.30%
Quality
1 /100
Poor ROE 1,358.66%
ROA 39.44%
Asset turnover 0.05x
Debt
0 /100
High Int. coverage -2.21x
Current ratio 0.05x
Net debt/EBITDA N/A
Stability
14 /100
Unstable Rev. volatility 24.55%
EPS volatility 159.20%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PRPH
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Ted William Karkus
Employees
19
Headquarters
Uniondale
Upcoming events
16 NOV
Earnings
Upcoming earnings report